Synthetic biology advances for pharmaceutical production.
Curr Opin Biotechnol 2015;
35:46-51. [PMID:
25744872 PMCID:
PMC4617476 DOI:
10.1016/j.copbio.2015.02.004]
[Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2014] [Revised: 02/11/2015] [Accepted: 02/12/2015] [Indexed: 01/12/2023]
Abstract
Synthetic biology is quickly moving from proof of concept to industrial application.
Pharmaceuticals are a promising target for advanced genetic engineering.
Genome sequence data indicate vast underexploited biosynthetic capacity.
Synthetic biology can create libraries of novel chemicals enriched for bioactivity.
Synthetic biology expands the range of available chassis organisms for industry.
Synthetic biology enables a new generation of microbial engineering for the biotechnological production of pharmaceuticals and other high-value chemicals. This review presents an overview of recent advances in the field, describing new computational and experimental tools for the discovery, optimization and production of bioactive molecules, and outlining progress towards the application of these tools to pharmaceutical production systems.
Collapse